Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study found that TSA restored the hair-inductive capacity of skin-derived precursors in mice by enhancing BMP gene expression and signaling through histone acetylation.

This study found that overexpression of the transcription factor Tcf3 accelerates keratinocyte migration and skin wound healing in mice, highlighting its potential as a therapeutic target for wound repair.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This abstract does not contain research results or findings.

This study demonstrates that YAP and TAZ are essential for initiating basal and squamous cell carcinomas in mice, and suggests targeting these pathways could be beneficial for treating skin cancers.

In this study, tacrolimus was as effective as clobetasol propionate in treating alopecia areata, suggesting it can serve as an alternative therapy option.

In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.

This article presents a toolkit created by the FTA to help transit agencies manage employees' use of medications that could impact public safety, but it reports no new results.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This study reports two cases of central serous chorioretinopathy developing after intralesional corticosteroid injections to the scalp for alopecia areata, suggesting a potential association that warrants cautious use and monitoring for ocular complications.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

This study in mice suggests that defects in hair follicles with mesenchymal TSC2 disruption may result from an impaired TGFβ1 response, indicating a potential novel treatment approach for tuberous sclerosis complex.

In a mouse model, this study found that LAM/TSC cells invaded the uterus and increased angiogenesis, while anti-EGFR antibody and rapamycin effectively reduced cell presence and blood vessel proliferation.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

Systemic mastocytosis may cause a type of hair loss called cicatricial alopecia.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study suggests that trichoscopy with a handheld dermatoscope may help differentiate temporal triangular alopecia from other localized alopecia by identifying specific hair features.